食品和药物管理局批准Emblaveo,这是治疗成人重腹部感染的新抗生素。 FDA approves Emblaveo, a new antibiotic for treating tough abdominal infections in adults.

林业发展局批准了Emblaveo,这是一种新的抗生素综合疗法,用于治疗治疗选择有限的成年人复杂的腹内感染(CIAI)。 The FDA has approved Emblaveo, a new antibiotic combination for treating complicated intra-abdominal infections (cIAI) in adults with limited treatment options. Emblaveo将抗生素Aztreonam与抗生素Avibactam相结合,Avibactam是一种抑制剂,防止抗生素分解,使其能有效抗抗药性抗长效细菌。 Emblaveo combines aztreonam, an antibiotic, with avibactam, an inhibitor that prevents antibiotic breakdown, making it effective against drug-resistant Gram-negative bacteria. 根据显示安全性和有效性的临床试验数据核准,到2025年Q3时,美国将可获得该数据。 Approved based on clinical trial data showing safety and efficacy, it will be available in the U.S. by Q3 2025.